Brakiterapi Gerçekten de Normal Dokular İçin Minimum Doz mu? Brakiterapi Kazaları, Dozimetrisi
Özet
Brakiterapi (BRT), radyoaktif kaynakların hedef dokunun içine, vücut boşluklarına veya yüzeyine yerleştirilmesiyle uygulanan, çevre normal dokularda hızlı doz düşüşü sağlayarak tümör hücrelerine lokal olarak çok yüksek radyasyon dozları ulaştıran kritik bir kanser tedavisi bileşenidir. Tarihsel süreçte Radyum-226 kullanımından yapay radyoizotoplara (İridyum-192, Kobalt-60, Sezyum-137, İyot-125, Palladyum-103) geçiş ve uzaktan kumandalı sonradan yüklemeli cihazların geliştirilmesi, çalışanların radyasyon maruziyetini azaltmış ve tedavi konforunu artırmıştır. Tedavi süresine, kaynak yükleme tipine ve doz hızına (LDR, MDR, HDR, PDR) göre sınıflandırılan bu yöntem, günümüzde iki boyutlu nokta hesaplamalarından üç boyutlu MRG ve BT kılavuzluğundaki hacimsel doz planlamalarına evrilerek doz optimizasyonunda üstün başarı sağlamıştır. Stereotaktik Vücut Radyoterapisi (SBRT) gibi modern harici teknikler daha kolay uygulanabilir alternatifler sunsa da, özellikle lokal ileri evre serviks kanseri gibi olgularda brakiterapinin sunduğu benzersiz radyobiyolojik avantajların ve dik doz gradiyentinin yerini tamamen alamamaktadır. Bununla birlikte, tümör regresyonu ve organ hareketleri nedeniyle her fraksiyonda adaptif yeniden planlama yapılması, normal dokuların maruz kaldığı dozları minimumda tutmak ve stenoz, nekroz, fistül gibi ciddi anatomik toksisite risklerini önlemek adına zorunludur. Makale, 1987 yılında Brezilya Goiânia'da yaşanan Sezyum-137 kazası gibi tarihsel nükleer trajedileri de hatırlatarak, bu karmaşık tedavi süreçlerinin yalnızca yüksek klinik deneyime sahip uzman ekipler tarafından yürütülmesi gerektiğini ortaya koymaktadır.
Brachytherapy (BRT) serves as a foundational modality in oncological management, characterized by the precise placement of radioactive sources directly within or adjacent to malignant tissues, thereby delivering escalating radiation doses to the tumor volume while ensuring an abrupt dose fall-off in peripheral healthy structures. The historical transition from natural Radium-226 to advanced synthetic radioisotopes—such as Iridium-192, Cobalt-60, Cesium-137, Iodine-125, and Palladium-103—complemented by remote automated afterloading technology, has significantly mitigated occupational radiation hazards and elevated clinical standard of care. Categorized by treatment duration, loading methodology, and dose rates (LDR, MDR, HDR, PDR), brachytherapy has evolved from conventional two-dimensional point-dose prescriptions into cutting-edge three-dimensional MRI and CT-guided volumetric dosimetry, which substantially refines dose optimization. While Stereotactic Body Radiotherapy (SBRT) presents a technically less demanding external alternative, clinical evidence underscores that it cannot fully replicate the exceptional radiobiological advantages and sharp spatial dose gradients of brachytherapy, particularly in locally advanced cervical malignancies. Nevertheless, due to intra-fraction organ motion and rapid tumor regression, systematic adaptive re-planning during each treatment session is clinically imperative to restrict normal tissue complications and avert debilitating toxicities like stenosis, necrosis, or fistulas. Synthesizing historical precedents such as the catastrophic 1987 Goiânia Cesium-137 contamination accident, the literature emphasizes that maximizing therapeutic outcomes while minimizing normal tissue morbidity necessitates execution exclusively by highly proficient, multidisciplinary clinical teams.
Referanslar
ICRU Report 38: Dose and Volume Specification for Reporting Intracavitary Therapy in Gynecology, March 1985 , pp. iii-23
ICRU Report 50: Prescribing, Recording and Reporting Photon Beam Therapy, September 1993, pp. iii-72.
ICRU Report 62: Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50), November 1999, pp. iii-52.
Stewart AJ. Helper JT, O’FarrellDA,Devlin PM, PriceLL, Dale RG, et al. Equivalent uniform dose for accelerated partial breast irradiation using the Mammo Sitea pplicator. Radiother Oncol. 2013.108(2):232-5.
Saw CB, Suntharalingam N. Quantitative assesment of interstitia limplants. Int J Radiat Oncol Biol Phys. 1991;20(1):135-9.
George D, KirisitisC,Hillbrand M, Dimopoulos J, Potter R. Image- guided radiotherapy for cervix cancer: high tech external beamtherapy versus high-tech brachytherapy. Int J Radiat Oncol Biol Phys 2008;71(4):1272-8.
Wazer DE. Kaufman S, CuttinoL, DiPetrillo T, Arthur DW. Accelereted partial breast irradiation: ananalysis of variables associated with late toxicitiy and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2006;64(2):489-95
Binnur Dönmez Yılmaz, Mustafa Ünsal Brakiterapi Okmeydanı Tıp Dergisi 29 (Ek sayı 1):35-40, 2013 doi:10.5222/otd.supp1.2013.035
Devlin, Phillip M. Brachytherapy: Applications and Technique, P.239,1st Edition Copyright ©2007 Lippincott Williams & Wilkins
.Turkiye Klinikleri J Radiat Oncol-Special Topics. 2017;3(1):60-71
Turkiye Klinikleri J Radiat Oncol-Special Topics. 2017;3(1):25-36
Mark J. Rivard, Bert M. Coursey et al. Update of AAPM Task Group No. 43 Report: A revised AAPM protocolfor brachytherapy dose calculations. Med. Phys. 31Ñ3Ö, March 2004
Lindegaard JC, Tanderup K ,Nielsen SK et al. MRI-guided 3D optimization significantly improves DVH parameters of pulsed-dose-rate brachytherapy in locally advenced cervical cancer. Int J Radiat Oncol Biol Phys 2008;71:756-764
GEC-ESTRO - ICRU 89 ICRU 89. Prescribing, Recording, and Reporting Brachytherapy for Cancer of the Cervix. Journal of the ICRU Vol 13 No 1–2 (2013) Report 89
Haie-Meder C, Pötter R, Van L et al. Recommendation s from Gynaecological (GYN) GEC ESTRO Working Group (I): concepts and terms ın 3D ımage based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI asseeement of GTV and CTV. Radiother Oncol 2005;74(3):235-245,
Pötter R, Haie-Meder C et al. Recommendation s from Gynaecological (GYN) GEC ESTRO Working group (II):. concepts and terms ın 3D ımage based 3D treatment planning in cervix cancer brachytherapy-3D dose volüme parameters and aspects of 3 D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 2006;78(1):67-77
Christian Kirisits , Stefan Lang ,Johannes Dimopoulos , Karin Oechs, Dietmar Georg, Richard Pötter Uncertainties when using only one MRI-based treatment plan for subsequent high-dose-rate tandem and ring applications in brachytherapy of cervix cancer. Radiother Oncol 2006;81(3):269-275,
Beriwal S, H.KimD.CoonR. MogusD.E.HeronX.LiM.S.Huq. Single Magnetic Resonance Imaging vs Magnetic Resonance Imaging/Computed Tomography Planning in Cervical Cancer Brachytherapy. Clin Oncol (R Coll Radiol) 2009;21:483-487
Tod MC, Meredith WJ A dosege system for use ın the treatment of cancer of uterıne cervıx . Br J 1938
www.americanbrachytherapy.org/guidelines
Viswanathan AN , Diomopoulos J, Krisits C et al. Computed tomography versus MRI based contouring in cervical cancer brachytherapy ; results of a prospective trial and preliminary guidelines for standardized contours. Int J. Radiat Oncol Biol Phys 2007; 68(2):491-8.
Hellebust TP, Tanderup K, Lervag C et al.Dosimetric impact of interobserver variability in MRI-based delineation for cervical cancer brachytherapy. Radiother Oncol 2013;107(1):13-19
Nag S, Bayer D. Friedland J. et al. American Brachytherapy Society (ABS) recommendiations for transperineal permenant bracytherapy of prostate cancer. Int J. Radiat Oncol Biol Phys 2000;46:221-223
Haie-Meder C, Richard Pötter, Erik Van Limbergen et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 2005;74(3):235-245
Han K, MilosevicM, Fyles A, et al. Trends ın the utilization of brachytherapy ın cervıcal cancer ın the United States. Int J Radiat Oncol Biol Phys 2013;87(1):111-9
Daniel G. Petreit. High dose Rate Brachytherapy in the Treatment of Cervical Cancer, National Institute of Health Consensus Development Conference on Cervical Cancer, Bethesda, Maryland: April 1-3, 1996.
GEC ESTRO Handbook of Brachytherapy.
. Nag S, Erickson B, Thomadsen B, Orton C, Demanes JD, Petereit D. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2000;48(1):201-11
Pötter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D imagebased anatomy, radiation physics, radiobiology. Radiother Oncol 2006;78(1):67-77
Han K, MilosevicM, Fyles A, et al. Trends ın the utilization of brachytherapy ın cervıcal cancer ın the United States. Int J Radiat Oncol Biol Phys 2013;87(1):111-9
Assenholt MS, Peterson JB, NielsenSK, et al A dose planning study on applicator guided stereotactic IMRT boost ın combination with 3DMRI based brachytherapy ın locally advanced cervical cancer. Acta Oncol 2008;47(7)1337-43.
Kari Tanderup , Patricia J Eifel , Catheryn M Yashar , Richard Pötter. Curative radiation therapy for locally advanced cervical cancer: brachytherapy is NOT optional. Int J Radiat Oncol Biol Phys 2014;88(3):537-9.
Bretislav Otahal , Martin Dolezel , Jakub Cvek , Ondrej Simetka et al. Dosimetric comparison of MRI-based HDR brachytherapy and stereotactic radiotherapy in patients with advanced cervical cancer: A virtual brachytherapy study. Rep Pract Oncol Radiother 2014;19(6):399-404.
Bulent Aydogan, Arno J Mundt, Brett D Smith, Loren K Mell et al. A dosimetric analysis of intensity-modulated radiation therapy (IMRT) as an alternative to adjuvant high-dose-rate (HDR) brachytherapy in early endometrial cancer patients.Int J.Radiat Oncol Biol Phys 2006;65(1):266-73
Shoichi FUKUDA, Yuji SEO, Hiroya SHIOMI, Yuji YAMADA, Toshiyuki OGATA et al. Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife. Radiat Res 2014;55(6):1114-21
History of Nuclear and Radiological Accidents in the World and Turkey DOI:10.4274/nts.2017.020Nucl Med Semin 2017;3:184-188
Jeffrey F. Williamson, X. Allen Li, and David J. Brenner. Physics and Biology of Brachytherapy. Perez&Brady’s and Practice of radiation oncology. Sixth Edition.2013. 422- 467.
Kemikler G., Aslay I. Brakiterapinin Radyobiyolojisi. Turkiye Klinikleri Radiat Oncol-Special Topics 2017;3(1):60-71.
Alexandra J. Stewart, Caroline L. Halloway, and Phillip M. Devlin. Clinical Applications of Brachytherapy: Low-Dose Rate and PulsedDose Rate. Perez&Brady’s and Practice of radiation oncology.Sixth edition.2013. 468- 487.
Subir Nag and Granger R. Scruggs. Clinical Aspects and Applications of High–Dose-Rate Brachytherapy. Perez&Brady’s and Practice of radiation oncology.Sixth edition. 2013.506- 524.
Dönmez YılmazB, Ünsal M. Brakiterapi. Okmeydanı Tıp Dergisi, 2013;29(Ek sayı 1):35-40
LENT SOMA scales for all anatomic sites. Int. J. Radiat. Oncol. Biol. Phys. 1995;31:1049– 1091. No authors listed.
Banerje R,Kamrava M. Brachytherapy in the treatment ofcervical cancer: a review. International Journal of Women’s Health 2014;6:555-564
